Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERASURE: Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque Psoriasis (Japan)
jRCT2080221490Phase 3
- Sponsor
- Novartis
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Secukinumab with Placebo (2 arms).
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2080221490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221490.